Clinical Policy: Electric Tumor Treating Fields (Optune)
Reference Number: PA.CP.MP.145
Effective Date: 01/18
Last Review Date: 10/2019

Description
Electric tumor treating fields (TTF), also known as alternating electric field therapy, are used for the treatment of glioblastoma, and are delivered by Optune® (NovoCure™), a portable medical device that generates low-intensity electric fields termed Tumor Treating Fields. TTF are believed to disrupt the rapid cell division exhibited by cancer cells, with the alternating electrical fields applied to the brain through electrodes placed on the scalp. The device is worn by the patient throughout the day and attached to the head by electrodes which creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

Policy/Criteria
I. It is the policy of PA Health & Wellness (PHW) that TTF therapy is **medically necessary** when meeting one of the following:
   A. Request is for an initial 90 days of TTF therapy and both of the following:
      1. One of the following indications:
         a. New diagnosis of glioblastoma, histologically confirmed, and all of the following:
            i. Glioblastoma is in the supratentorial region;
            ii. Member has good performance status, as defined by a Karnofsky Performance Status rating of ≥ 60;
            iii. Alternating electric field therapy will be delivered in conjunction with temozolomide after standard surgical and radiation therapies have been completed;
         b. Recurrent glioblastoma, histologically- or radiologically- confirmed and both of the following:
            i. Glioblastoma is in the supratentorial region;
            ii. Alternating electric field therapy will be used as a monotherapy, after standard treatment with surgery, radiation, and chemotherapy;
   2. None of the following contraindications:
      a. Implanted medical device such as deep brain stimulator, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, or programmeable shunts;
      b. Skull defect such as a missing bone with no replacement, or bullet fragment;
      c. Pregnancy;
      d. Known sensitivity to conductive hydrogels (e.g., gels used on electrocardiogram [ECG] stickers or transcutaneous electrical nerve stimulation [TENS] electrodes);
   B. Request is for an additional 90 days of therapy and there has been no disease progression in the last 90 days of TTF therapy.

II. It is the policy of PHW that TTF therapy is **investigational and not medically necessary** for all other indications.
III. It is the policy of PHW that computer mapping software (NovoTal™) for planning TTF therapy is **investigational and not medically necessary** for all indications, as there is insufficient evidence to establish the efficacy of these products in the long-term outcomes of patients receiving TTF therapy.

**Background**

*Optune Product Description*

Optune (formerly NovoTTF-100A) produces alternating electrical fields within the human body that disrupt the rapid cell division exhibited by cancer cells, with the alternating electrical fields applied to the brain through transducer arrays placed on the scalp. Electric TTF alter the tumor cell polarity at an intermediate frequency (on the order of 100-300 kHz). The frequency used for a particular treatment is specific to the cell type being treated (e.g., 200kHz for GBM). In contrast, the TTF have not been shown to have an effect on cells that are not undergoing division. Since most normal adult brain cells proliferate very slowly, if at all, they are hypothesized to be little affected by the TTF. Testing demonstrates no differences between treated and control animals in histology of the major internal organs (including the brain), blood examination, cardiac rhythm, body temperature, or in animal behavior. In addition, because the fields alternate so rapidly, they have no effect on normal quiescent cells nor do they stimulate nerves and muscles. It is noted that, because TTF are only applied to the brain, they have no effect on rapidly proliferating cells in the rest of the body. The intensities of the electric fields within the tissues are very small and do not result in any meaningful increase in tissue temperature. Thus, TTF application has the advantage of being highly selective and is not expected to be associated with significant toxicity.

**Position Statement**

Guidelines from the National Comprehensive Cancer Network (NCCN) on central nervous system cancers, recommend alternating electrical fields therapy as a treatment option for newly diagnosed glioblastoma (2A- uniform consensus, based on low-quality evidence). The NCCN guidelines state TTF is recommended “for patients with good performance status and either methylated or unmethylated/indeterminate MGMT promoter status,” in conjunction with standard brain radiation therapy plus concurrent temozolomide and adjuvant temozolomide. For recurrent glioblastoma, NCCN gives alternating electrical field therapy a 2B rating (consensus based on low-quality evidence).

**Evidence for Optune**

Initial FDA approval for recurrent glioblastoma was based on Stupp et al.’s 2012 phase III clinical trial that randomized 237 patients to chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-point was improvement of overall survival. Patients were randomized to TTF alone or active chemotherapy control. Responses were more common in the TTF arm (14% versus 9.6%, p=0.19) and TTF-related adverse events were mild. Quality of life analyses favored TTF therapy in most domains. The investigators concluded that no improvement in overall survival was demonstrated. However, efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma. Toxicity and quality of life measures favored TTF.
The FDA based its approval of the newly diagnosed glioblastoma indication of the Optune device on results from a 2015 clinical trial by Stupp et al. The EF-14 trial included 695 patients newly diagnosed with GB, and compared those who used Optune with temozolomide to those receiving temozolomide alone. Patients who used the device along with temozolomide lived, on average, about seven months with no disease progression compared to four months for those who had the drug alone. The Optune plus temozolomide group survived for an average of 19.4 months after starting treatment compared to 16.6 months for those who were treated with only temozolomide. One critique of this study is that the study was terminated at the pre-planned intermediate analysis due to success of the TTF treatment. With the newly diagnosed glioblastoma indication, Optune can be used for GBM before the disease progresses. For newly diagnosed GBM, Optune is not intended to be used as a substitute for standard treatments, but rather as an adjunct therapy, and should not be used without a physician’s supervision.

Hayes conducted a review of the available literature on TTF, noting that overall the body of evidence was of fair to very poor quality, although it was consistently positive. Hayes found the evidence to be stronger for the use of TTF for recurrent disease as opposed to newly diagnosed disease, as there were more supportive studies for recurrent disease at the time of publication (2 vs. 6). Out of the 10 studies they reviewed, pertaining to the use of TTF in patients with GBM and select other cancers, two were of fair quality, and the other eight ranged from poor quality to very poor quality. The two fair quality trials were those conducted by Stupp et al. in 2012 and 2015, although these were noted to have limitations such as lack of a sham intervention and significant loss to follow up (22% and 20%, respectively).

A post-hoc analysis of Stupp et al.’s E-14 trial of TTF plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTF plus physician’s choice of chemotherapy versus chemotherapy alone after first recurrence. Median overall survival in the TTF plus chemotherapy was 11.8 months versus 9.2 months for the chemotherapy only group (p=.049). TTF demonstrated low toxicity, consistent with previous studies. Limitations of this analysis are its post-hoc nature, as well as the crossover of 13 patients from the temozolomide only group to the TTF plus chemo group after approval and commercial availability of TTF for recurrent GBM.

Vymazal et al. analyzed the response patterns in individuals who exhibited an objective response to TTF in two previous studies in order to evaluate the baseline characteristics of those individuals who responded and to evaluate the relationship between compliance with use and efficacy outcomes. The analysis was completed on one pilot study (n=10) and a phase III trial (n=237) in which TTF was compared to standard chemotherapy. Between both studies, TTF was administered as monotherapy in 130 individuals. Across both trials, there was a 15% response rate (16/110 with a 4% complete response rate). There were no significant differences in baseline characteristics between the responder and nonresponder groups. In those in which a response was noted, there was frequently a delayed response; the tumor would initially continue to grow before responding to treatment. Analysis supported that an increase in compliance was associated with better treatment response and longer OS. The extent of treatment response in those who exhibited a response was dependent on compliance (p<0.001).
Although Optune is promising for the treatment of newly diagnosed glioblastoma, there is insufficient evidence to promote it as standard of care at this time. Evidence is stronger for recurrent glioblastoma which has been previously treated with radiation, surgery and chemotherapy.

**NovoTal**

The NovoTal system (Novocure) is a computer software planning tool that helps direct placement of transducer arrays for TTF therapy. Few studies have evaluated outcomes of TTF planned by physicians with and without the use of NovoTal, and these are limited to a case series, physician use study, and two review articles. Additionally, many of the authors reported ties to Novocure.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4555</td>
<td>Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only</td>
</tr>
<tr>
<td>E0766</td>
<td>Electrical stimulation device used for cancer treatment, includes all accessories, any type</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Codes that Support Coverage Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-CM Code</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>C71.0 - C71.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>References reviewed and updated. Background updated. Codes reviewed.</td>
<td>03/18 CPC 04/18 PHW</td>
<td></td>
</tr>
<tr>
<td>Added contraindications per product operating instructions. Added that treatment is for 90 days initially, or for an additional 90 days at a time and there was no evidence of disease progression in last 90 days on TTF therapy. Specialist reviewed.</td>
<td>10/19 PHW</td>
<td></td>
</tr>
</tbody>
</table>
References

1. Novocure. Optune Instructions for Use. Document Number QSD-QR-703. Revision 01. Issue Date: July 201 QSD-QR-703. Revision 01. Issue Date: July 2016.